Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating, because that familiar routine of meetings and deadlines and what-not has now returned. You knew this moment would come, yes? So please join as we hoist another cup of stimulation in hopes of coping with the onslaught. Our flavor today, by the way, is a delightful mix of coconut, caramel, and mocha. Yum. Meanwhile, here are some tidbits to provide another sort of stimulation. Hope you have a smashing day and please do keep in touch …

Brexit may affect the cost of drugs and hit U.K. pharmaceutical investment, a government committee head  warns, the BBC reports. Several large drug makers also expressed concern about disruption to supply chains, clinical trials, and recruiting if the U.K. does not withdraw in an orderly manner from the European Union, The Telegraph says. Meanwhile, a U.S.-based life-sciences investment fund, with backing from GlaxoSmithKline (GSK), plans to invest up to $1 billion to create a large biotech company in the U.K., according to The Financial Times.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.